Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma
Part of paid clinical trials in Mobile, Alabama.
- Sponsor
- Celgene
- Study ID
- NCT06356129
- Phase
- PHASE3
- Status
- Active Not Recruiting
Conditions
- Large B-cell Lymphoma
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 80 Years
- Healthy Volunteers
- Not accepted
Interventions
- Golcadomide — DRUGSpecified dose on specified days
- Placebo — DRUGSpecified dose on specified days
- Rituximab — DRUGSpecified dose on specified days
- Cyclophosphamide — DRUGSpecified dose on specified days
- Doxorubicin — DRUGSpecified dose on specified days
- Vincristine — DRUGSpecified dose on specified days
- Prednisone — DRUGSpecified dose on specified days
Study Details
The purpose of this study is to compare the effectiveness and safety of golcadomide in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy vs placebo in combination with R-CHOP chemotherapy in participants with previously untreated high-risk large B-cell lymphoma (LBCL).
Key Dates
- Start date
- Jun 19, 2024
- Status verified
- Feb 2026
- Primary completion
- Aug 14, 2028
- Completion
- Nov 20, 2029
Study Design
- Enrollment
- 850 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Golcadomide + R-CHOP (Rituximab, Doxorubicin, Vincristine, Cyclophosphamide, Prednisone)
- Placebo Comparator: Placebo + R-CHOP
Primary Outcome Measure
Progression-free survival (PFS) assessed by the Investigator [ Time Frame: Up to approximately 67 months ]
Locations (46)
Find similar trials in Mobile, AL
Related Studies
- CAR-T Followed by Bispecific AntibodiesPHASE2 · Recruiting · Abramson Cancer Center at Penn Medicine · Omaha, Nebraska
- A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell TherapyPHASE2 · Recruiting · M.D. Anderson Cancer Center · Houston, Texas
- A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell MalignanciesPHASE1/PHASE2 · Recruiting · CRISPR Therapeutics AG · Westwood, Kansas
- Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and/or Refractory Second Line High-Risk Non-Hodgkin Lymphoma After Standard of Care Axi-CelPHASE1 · Recruiting · Stanford University · Palo Alto, California